ADVERSE EFFECT OF INSOMNIA ON BLOOD LIPIDS IN PATIENTS WITH HYPERTENSION

Insomnia is a risk factor for the development of arterial hypertension, obesity, type 2 diabetes mellitus, cardiac rhythm disorders, and myocardial infarction. At the same time, insomnia is one of the most frequent non-cardiac complaints in patients with cardiovascular diseases. The aim of the work was to study the presence of possible relationships between insomnia and the level of blood lipids. Materials and methods. A cross-sectional study involving 118 patients was conducted. Criteria for inclusion in the study were age over 45 years, the presence of essential hypertension. All patients included the study underwent sampling of 7 ml of venous blood in the morning under fasting conditions. The content of total cholesterol (TCS), triglycerides (TG), high-density lipoprotein cholesterol (HDL CS) was determined by enzymatic method on a biochemical analyser Humalyzer 2000. The patient was interviewed by a pre-trained study doctor.  Results. In the article a relationship between total cholesterol, low-density lipoprotein cholesterol and the presence of insomnia has been established and proved by statistical model. The overall statistical model accuracy is 89.6 % and statistical significance p < 0.005. Accuracy of insomnia prediction is 85.7 % by level of total cholesterol (TCS) and patient interview data. Only one model with best accuracy exists and it was estimated at the article. Conclusions. Relationship between total cholesterol, low-density lipoprotein cholesterol and the presence of insomnia has been established and proved by statistical model. Accuracy of insomnia prediction is 85.7 % by level of total cholesterol (TCS) and patient interview data

Effect of amlodipine on the manifestations of chronic insomnia in hypertensive patients with type 2 diabetes mellitus

Background: The aim of the study was to assess the association between antihypertensive therapy and the manifestations of insomnia in patients with arterial hypertension (AH) and type 2 diabetes mellitus (T2DM). Material and methods: The study included 120 hypertensive patients with and without T2DM (among them there were 60 patients with insomnia). The study consisted of three stages. The first stage was conducted as a cross-sectional study, during which an association was established between different antihypertensive products and the presence of insomnia in the study population. The second and third stages were a prospective study, during which a modification of the therapy to reduce the manifestations of insomnia was performed. Results: It was found that patients receiving amlodipine in the combination antihypertensive therapy had insomnia manifestations much less frequently as compared to indapamide. A statically significant decrease in blood pressure (BP) and a higher proportion of patients with target BP were observed in both groups. Replacement of indapamide with amlodipine was shown to improve sleep quality. Thus, the number of patients with insomnia significantly decreased in both groups. After correction of antihypertensive therapy after 12 months, all patients were assessed for sleep disorders. The incidence of insomnia was found to be significantly reduced in both groups after changing therapy from indapamide to amlodipine. Conclusions: Correction of antihypertensive therapy, namely the replacement of indapamide with amlodipine, contributes to an improvement in BP, quality of life, and a reduction in the proportion of patients with insomnia

The impact of sleep disorders in the formation of hypertension

Hypertension is one of the most common chronic non-communicable disease in the world. Risk factors, methods of prevention and treatment of hypertension have been sufficiently studied. However scientists are still looking for pathogenetic mechanisms of its development. At the same time 36.9% of patients with hypertension had different sleep disorders. Patients with insomnia have a 21% higher risk of developing hypertension compared with those who have quality sleep. Hypnotics are given up to 15% of patients with hypertension. Hypnotics have been shown to increase the risk of cardiovascular events. 44.1% of patients with established diseases of the cardiovascular system have problems with the quality or duration of sleep. At this time, hypertension and sleep disorders are considered mutually aggravating diseases

PEMBENTUKAN KERAK KALSIUM KARBONAT (CaCO3) DALAM PIPA BERALIRAN LAMINER DENGAN PARAMETER KONSENTRASI LARUTAN DAN PENAMBAHAN ADITIF ASAM MALAT

Kerak merupakan masalah yang cukup serius  yang dijumpai pada sebagian besar proses industri, yaitu terjadinya pengendapan garam pada dinding-dinding peralatan proses aliran fluida, terutama pada permukaan transfer panas dan permukaan alat-alat evaporasi. Kerak yang menumpuk pada pipa-pipa saluran,  lubang-lubang dan beberapa bagian aliran pada proses aliran fluida dapat menyebabkan gangguan yang serius pada pengoperasian, karena penumpukan kerak ini dapat mengakibatkan terjadinya korosi dan kerusakan pada peralatan proses produksi. Dalam penelitian  ini dilakukan eksperimen tentang CaCO3  dalam pipa uji dengan membuat larutan dari CaCl2  dan NaCO3  dengan konsentrasi larutan masing-masing 3500 ppm, 4000 ppm dan 4500 ppm dengan laju alir 30 ml/menit pada temperatur kamar. Zat aditive yang digunakan adalah asam malat dengan konsentrasi  3 dan 5 ppm.  Kata kunci : asam malat, kalsium karbonat, konsentrasi laruta

Evinacumab for Homozygous Familial Hypercholesterolemia

BACKGROUND Homozygous familial hypercholesterolemia is characterized by premature cardiovascular disease caused by markedly elevated levels of low-density lipoprotein (LDL) cholesterol. This disorder is associated with genetic variants that result in virtually absent (null–null) or impaired (non-null) LDL-receptor activity. Loss-offunction variants in the gene encoding angiopoietin-like 3 (ANGPTL3) are associated with hypolipidemia and protection against atherosclerotic cardiovascular disease. Evinacumab, a monoclonal antibody against ANGPTL3, has shown potential benefit in patients with homozygous familial hypercholesterolemia. METHODS In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned in a 2:1 ratio 65 patients with homozygous familial hypercholesterolemia who were receiving stable lipid-lowering therapy to receive an intravenous infusion of evinacumab (at a dose of 15 mg per kilogram of body weight) every 4 weeks or placebo. The primary outcome was the percent change from baseline in the LDL cholesterol level at week 24. RESULTS The mean baseline LDL cholesterol level in the two groups was 255.1 mg per deciliter, despite the receipt of maximum doses of background lipid-lowering therapy. At week 24, patients in the evinacumab group had a relative reduction from baseline in the LDL cholesterol level of 47.1%, as compared with an increase of 1.9% in the placebo group, for a between-group least-squares mean difference of –49.0 percentage points (95% confidence interval [CI], –65.0 to –33.1; P 0.001); the between-group least-squares mean absolute difference in the LDL cholesterol level was –132.1 mg per deciliter (95% CI, –175.3 to –88.9; P 0.001). The LDL cholesterol level was lower in the evinacumab group than in the placebo group in patients with null–null variants (–43.4% vs. +16.2%) and in those with non-null variants (–49.1% vs. –3.8%). Adverse events were similar in the two groups. CONCLUSIONS In patients with homozygous familial hypercholesterolemia receiving maximum doses of lipid-lowering therapy, the reduction from baseline in the LDL cholesterol level in the evinacumab group, as compared with the small increase in the placebo group, resulted in a between-group difference of 49.0 percentage points at 24 weeks. (Funded by Regeneron Pharmaceuticals; ELIPSE HoFH ClinicalTrials.gov number, NCT03399786.